• Explore /
  • Videos & Slides
  • / Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRAS<sup>G12C </sup>inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).

Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).

Abstract Video & Slides Poster

Presenter

David S. Hong

David S. Hong, MD

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT04185883

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS2669)

DOI

10.1200/JCO.2021.39.15_suppl.TPS2669

Abstract #

TPS2669

Poster Bd #

Online Only

Abstract Disclosures

Similar Videos & Slides

Speaker: Ferdinandos Skoulidis, PhD

Speaker: Hiroaki Akamatsu, MD, PhD

Speaker: David S. Hong, MD

Speaker: Mustafa Ozguroglu, MD